tbuckley/cabot-search huggingface dataset:
Sensory Deprivation
Authors: Eugene L. Bliss
Journal: JAMA (1962)

The disturbing effects of isolation on man have been known in anecdotal form for many years, as witness accounts of feral children, lonely explorers, and prisoners in solitary confinement, but only in the last few years have efforts been made to investigate the nature of these processes in the laboratory. Hebb and his colleagues in Montreal and later Lilly in Bethesda reported the dramatic consequences of experimental "sensory isolation." Their observations of hallucinations and personality disorganization attracted wide attention and led to a proliferation of studies, as well as to many speculations. The evidence indicates that alterations in sensory input, either by radical reduction, repatterning, or overloading may have profound influence on psychological processes, but how and why this should be is far from clear. Riesen summarizes some experiences with early deprivation in animals and describes the behavioral deficits, hyperirritability, and seizures which ensue. Four cases of unexplained confusion in
Outlines of Zoölogy.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical impact of expanded <i>BRAF</i> mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR Monoclonal Antibodies by Comprehensive Cancer Genomics).
Authors: Satoshi Yuki, Takayuki Yoshino, Katsuya Tsuchihara, Eiji Shinozaki, Kei Muro, Tomohiro Nishina, Kensei Yamaguchi, Kiwamu Akagi, Kentaro Yamazaki, Takeharu Yamanaka, Shogo Nomura, Satoshi Fujii, Hiroyasu Esumi, Yukiko Abe, Atsushi Ohtsu
Journal: Journal of Clinical Oncology (2015)

11038 Background: BRAFV600E mutation has been recognized as a prognostic marker in patients (pts) with metastatic colorectal cancer (mCRC). Several studies have consistently shown a significant association between the presence of BRAFV600E mutation and resistance to anti-EGFR antibody therapy in pts with previously treated mCRC while there are few reports on the clinical impact of minor BRAF mutations. Methods: The BREAC trial was a multicenter, retrospective study to investigate the novel biomarkers of anti-EGFR antibody therapy. RAS and BRAF mutations were detected by targeted sequencing using FFPE materials of mCRC pts who received anti-EGFR antibody after a failure to standard therapies. Progression-free survival (PFS), overall survival (OS), and response rate (RR) were evaluated according to expanded RAS/BRAF mutational status. Results: Of 184 pts enrolled in the study, RAS/BRAF testing was succeeded in 150 pts. Patients characteristics were as follows; male/female 87/63, median age 63.5 years (range, 28-85), PS 0/1/2 81/65/4. Median PFS, OS, and RR were 4.0 months, 12.4 months, and 21%, respectively. Expanded RAS and BRAF mutations were detected in 40 pts (26.7%, KRAS/NRAS 29/11) and in 16 pts (10.7%, BRAFV600E/other 9/7), respectively. Observed BRAF mutations other than BRAFV600E were located at kinase domain. The clinical outcomes of other BRAF mutations were worse similar to those of BRAFV600E and expanded RAS mutations (Table). Conclusions: Expanded BRAF mutations might predict a lack of response for mCRC pts who received anti-EGFR antibody. Further investigation is warranted to confirm the clinical impact of expanded BRAF mutations. RAS/BRAF all wild RAS/BRAF any mut RAS any mut BRAF V600E mut BRAF other mut n 94 56 40 9 7 Median PFS (months) 5.9 2.1 2.1 1.6 2.3 HR = 3.49 p < 0.0001 Median OS (months) 14.5 6.4 6.3 4.6 8.1 HR = 2.14 p < 0.0001 RR (%) 31.9 1.8 2.5 0.0 0.0
Flushing and Morbid Blushing; Their Pathology and Treatment.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma
Authors: Ajai Chari, Hearn Jay Cho, Siyang Leng, Amishi Dhadwal, Gillian Morgan, Lisa La, Katarzyna Garcia, Crystle Carter, Donna Catamero, Juliet Escalon, Erika Florendo, Nadege Stevens, Daniel Verina, Moon-hee Yum, Jude Gullie, Elaine Chan, Sundar Jagannath, Violetta V Leshchenko, Alessandro Lagana, Jingjing Qi, Manishkumar Patel, Kim-Schulze Seunghee, Samir Parekh
Journal: Blood (2015)
Glucose measurements and clinical correlations
Authors: D. C. Niejadlik
Journal: JAMA (1973)

Various methods for glucose analysis of whole blood and plasma are currently utilized and the clinician should be familiar with them when interpreting a glucose value. Three methods of glucose analysis of whole blood and plasma have been evaluated: Somogyi-Nelson, hexokinase, and copper reduction. Linear regression equations were derived and statistical evaluation by analysis of variance revealed highly significant results. Plasma glucose as measured by the copper reduction technique is approximately 17% higher than whole blood glucose measured by the Somogyi-Nelson method. A consistent 5-mg/deciliter difference in plasma glucose was present between the two plasma glucose procedures, the enzymatic method, and the copper reduction method.
Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
Authors: Daniel A. Goldstein, Bilal B. Ahmad, Qiushi Chen, Turgay Ayer, David H. Howard, Joseph Lipscomb, Bassel F. El-Rayes, Christopher Flowers
Journal: Journal of Clinical Oncology (2015)

658 Background: Regorafenib was approved by the FDA in 2012 for the management of previously treated metastatic colorectal cancer (mCRC). It is now the standard of care in the third-line setting. Compared to placebo it improves median overall survival by 1.4 months but is associated with adverse effects and additional cost. The objective of this study was to examine the cost-effectiveness of regorafenib compared to best supportive care for patients receiving third-line treatment for mCRC. Methods: We developed a Markov model to compare the cost and effectiveness of regorafenib compared to best supportive care in the third-line treatment of mCRC based on randomized data from the CORRECT trial. Weibull models were fitted to the published overall and progression-free survival curves, and were used to extrapolate the cause-specific mortality and progression risks. Costs for administration and management of adverse events were based on Medicare reimbursement rates for hospital and physician services, and drug costs based on the Medicare average wholesale prices (all in 2014 US $). Health outcomes were measured in life years (LYs) and quality-adjusted life years (QALYs). Quality of life adjustments were calculated based on health utility values in the CORRECT trial and toxicity disutilities and durations were included for the most common toxicities: hand/foot syndrome, diarrhea, and hypertension. Model robustness was addressed by univariate and probabilistic sensitivity analyses (PSA). Results: In the model, regorafenib provided an additional 0.06 QALYs (0.12 LYs) at a cost of $40,373. The incremental cost-effectiveness ratio (ICER) was $734,153/QALY. In all one-way sensitivity analyses, the ICER of regorafenib was &gt;$550,000/QALY. The ICER of regorafenib was greater than $200,000/QALY in &gt;99% of PSAs. Conclusions: This is the first U.S.-based cost-effectiveness analysis of regorafenib in mCRC, and our findings show that regorafenib provides minimal incremental benefit at high incremental cost per QALY. The ICER of regorafenib could be improved by use of an effective biomarker to select patients most likely to benefit, or by a lower price for payers.
Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS
Authors: Christopher Kornfeld, Mickaël J.-Y. Ploquin, Ivona Pandrea, Abdourahmane Faye, Richard Onanga, Cristian Apetrei, Virginie Poaty-Mavoungou, Pierre Rouquet, Jérôme Estaquier, Lorenzo Mortara, Jean-François Desoutter, Cécile Butor, Roger Le Grand, Pierre Roques, François Simon, Françoise Barré-Sinoussi, Ousmane M. Diop, Michaela C. Müller-Trutwin
Journal: Journal of Clinical Investigation (2005)

Due to an error in manuscript preparation, an incorrect shRNA sequence for IRS2 was published.The correct hairpin sequence is a 19-nt stretch beginning from nt 703 of the published IRS2 cDNA sequence (XM_357863).The oligonucleotides cloned into the U6 construct for the IRS2U6 adenovirus are as follows: tcgagGTGACGCTGCAGCTTATGAttcaagagaTCATAAGCTGCAGCGTCACttttt (forward) and ctagAAAAAGTGACGCTGCAGCTTATGAtctcttgaaTCATAAGCTGCAGCGTCACc (reverse).In addition, the shRNA cassettes were cloned into the adenoviral cosmid pAxcwit, which lacks a promoter, and not the cosmid pAxCAwtit, as published..
CALCIUM CHELATION THERAPY IN CARDIAC ARRHYTHMIAS
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver Failure Associated with the Dietary Supplement LipoKinetix
Journal: Annals of Internal Medicine (2002)

Summaries for Patients16 April 2002Liver Failure Associated with the Dietary Supplement LipoKinetixSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-8-200204160-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Dietary supplements, unlike drugs, are not evaluated by the U.S. Food and Drug Administration (FDA) before they are released for sale. In general, as long as manufacturers do not claim that their product cures or controls a particular disease, that product can be marketed as a dietary supplement. Adverse effects sometimes occur with use of dietary supplements, and manufacturers are not required to collect data about adverse effects or to report this information to the FDA. Information about adverse effects becomes public knowledge only when a physician or ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Severe Hepatotoxicity Associated with the Dietary Supplement LipoKinetix.” It is in the 16 April 2002 issue of Annals of Internal Medicine (volume 136, pages 590-595). The authors are JT Favreau, ML Ryu, G Braunstein, G Orshansky, SS Park, GL Coody, LA Love, and T-L Fong.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSevere Hepatotoxicity Associated with the Dietary Supplement LipoKinetix Joya T. Favreau , Mina L. Ryu , Glenn Braunstein , Greg Orshansky , Sean S. Park , Gary L. Coody , Lori A. Love , and Tse-Ling Fong Metrics 16 April 2002Volume 136, Issue 8Page: I-42KeywordsAutoimmune diseasesAutoimmune hepatitisDrugsFood and Drug AdministrationHepatitis AInfectious diseasesLiverLiver diseasesViral diseasesWeight loss ePublished: 16 April 2002 Issue Published: 16 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC.
Authors: V. L. Keedy, B. Lu, L. Horn, Y. Shyr, C. F. Winkler, D. P. Carbone, A. Sandler
Journal: Journal of Clinical Oncology (2011)

7046 Background: One third of patients (pts) with NSCLC present with localized, unresectable disease. Concurrent chemoradiotherapy is well established with weekly paclitaxel and C with median survival of ~14 months. Nanoparticle albumin-bound (nab) paclitaxel (nP) is a cremophor-free formulation of paclitaxel designed to improve solubility and intra-tumor delivery. This phase I trial evaluates weekly nP + C + TRT in pts with unresectable stage III NSCLC. Methods: Pts with inoperable Stage IIIA or IIIB NSCLC, PS 0-1, and FEV 1 >800 ml entered escalating dose cohorts in a modified 3+3 design of nP weekly, beginning at 40 mg/m2 and increasing by 20 mg/m2 increments, in combination with C (AUC 2) weekly for 7 weeks and concurrent RT 66 Gy/33 fractions by either 3D conformal or intensity-modulated techniques. Pts received 2 cycles of consolidation therapy with full dose nP (100 mg/m2 weekly for 3 weeks) and C (AUC 6 on day one of each cycle) every 21d. The DLT period is defined as the concurrent chemoradiation period. Results: Eleven pts were enrolled. Ten pts were treated at 2 dose levels of nP, 40mg/m2 (6 pts) and 60mg/m2 (4 pts). One pt signed consent and then withdrew. Six pts were treated at 40mg/m2 with no DLT. Four pts were treated at 60mg/m2 with 2 DLT of radiation dermatitis and esophagitis. During concurrent treatment, Grade 2 toxicities were fatigue, dehydration, nausea, dysphagia, esophagitis, mucositis, hypoxia, neutropenia, anemia, and thrombocytopenia, and Grade 3 toxicities were neutropenia, mucositis, esophagitis, and dermatitis. No grade 4 toxicities were seen during concurrent treatment. Ten pts were evaluable for response with 9 PR and 1 SD. Seven patients have progressed 3, 5, 6, 7, and 8, 16 and 20 months after enrollment, and 3 patients remain stable at 2, 4, and 28 months. The recommended Phase II dose of weekly nP is 40mg/m2. Conclusions: Weekly nP is safe and well tolerated at 40mg/m2 when used in combination with weekly C (AUC2) and RT (66Gy) with AEs expected for concurrent chemoradiotherapy. A Phase II study to further evaluate this regimen is underway.
BRACES IN SPINAL CURVATURE.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Varia
Authors: R.A. Pierloot, W. Wellens, M.E. Houben, Peter E. Sifneos, Finn Askevold, Mels A. de Jong, Anton W. van den Bergh, Arnold J. de Jong, O.W. Schonecke, W. Schüffel, E.J. Pinter, G. Peterfy, J.M. Cleghorn
Journal: Psychotherapy and Psychosomatics (1975)
Patient rejection of lithium carbonate prophylaxis
Authors: P. Polatin
Journal: JAMA (1971)

In the milder forms of manic-depressive disorders, many patients refuse to continue with lithium carbonate as a prophylactic agent for the following reasons: (1) Creative patients feel that the lithium carbonate acts as a "brake," preventing productivity and interfering with the earning of a livelihood. (2) The hypomanic phase is so enjoyable that rather than eliminate or limit it, they prefer to take their chances on the possibility that a depression will not recur. (3) Denial of the chronicity of the illness lies behind denial of the need to ingest lithium carbonate indefinitely.
THU0367 Fast Relapse Upon Discontinuation of Tumor Necrosis Factor Blocking Therapy in Patients with Peripheral Spondyloarthritis
Authors: J. Paramarta, T. Heijda, D. Baeten
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Tumour necrosis factor (TNF) blockade is highly effective for the treatment of spondyloarthritis (SpA). Unfortunately, in axial SpA, anti-TNF therapy discontinuation leads to fast disease relapse in almost all patients. However, what happens upon discontinuation of anti-TNF therapy in peripheral SpA remains unknown. <h3>Objectives</h3> The aim of this study was to assess persistent remission versus relapses after anti-TNF therapy discontinuation in peripheral SpA. <h3>Methods</h3> Twenty six adalimumab-treated patients with peripheral SpA not fulfilling the criteria for ankylosing spondylitis or psoriatic arthritis<sup>1</sup> were included in this study. Patients had received either 12 (n=12) or 24 weeks (n=14) of adalimumab treatment before discontinuation of the anti-TNF therapy. After discontinuation patients were prospectively followed for 16 weeks and seen for a relapse visit upon worsening of symptoms. Relapse was defined as increase of ≥1 swollen joint, or ≥2 points in patient's or physician's global assessment of disease activity or Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). <h3>Results</h3> At baseline (defined as the moment of interruption of adalimumab), disease activity scores were low (Table 1). Eleven patients (42%)had reached a 66 swollen joint count (SJC66) of zero and 14patients(54%) an Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease. After anti-TNF treatment discontinuation there was a significant increase in all disease activity parameters (Table 1). Nineteen patients (73%) experienced a relapse with a mean time to relapse of 10.0±3.2 weeks. Moreover, only 4 patients (16%) maintained a SJC66 of zero or ASDAS inactive disease over 16 weeks. Univariate analysis did not identify parameters (including treatment duration prior to discontinuation, disease activity parameters, and demographic or clinical characteristics) to be significantly associated with the occurrence of relapse. However, the time to relapse correlated with the duration of adalimumab treatment (R=0.722, p&lt;0.001 by Pearson correlation test) and a low SJC66 at baseline (R= –0.585, p=0.002). <h3>Image/graph</h3> <h3>Conclusions</h3> More than 70% of the peripheral SpA patients show a rapid relapse within 16 weeks after interruption of successful TNF blockade. <h3>References</h3> Paramarta JE, De Rycke L, Heijda TF, <i>et al.</i> Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. <i>Ann Rheum Dis</i> 2012 [Epub ahead of print] <h3>Disclosure of Interest</h3> None Declared
In Reply
Authors: J. Douglas Rizzo, Mark R. Somerfield, Karen L. Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L. Bennett, David F. Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Carole B. Miller, Mark U. Rarick, David H. Regan, Alan E. Lichtin
Journal: Journal of Clinical Oncology (2008)